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Abstract: Tamoxifen was the first targeted anticancer agent for breast cancer patients and its 
effects on reduction of breast cancer events and improvement in overall survival are undisputed. 
Hence, it has long been considered an essential part of patient care. Recent results of several 
large adjuvant hormonal trials evaluating the use of aromatase inhibitors in comparison with the 
previous standard of five years of tamoxifen has led to a paradigm shift, ensuring the   inclusion 
of an aromatase inhibitor as part of standard endocrine therapy for most postmenopausal women 
diagnosed today with estrogen receptor-positive breast cancer. However, one could argue 
that despite statistically significant improvements in breast cancer events, an overall survival 
advantage has not been clear. In this review, we discuss recent genomic and molecular data 
pertaining to estrogen receptor-positive breast cancer and how this knowledge may aid clinicians 
to prescribe adjuvant hormonal treatment in the future. A combination of gene expression and 
genetic aberration markers may be most useful in discerning a population that is still appropriate 
for adjuvant tamoxifen treatment.
Keywords: tamoxifen, aromatase inhibitors, resistance, prediction, mutation, endocrine 
therapy, PI3K
Introduction
Hormonal therapy is considered an essential part of the management of patients with 
estrogen receptor (ER)-positive breast cancer. Immunohistochemically confirmed 
presence of ER is the most important factor that predicts response to hormonal 
manipulation.
The ER is a transcription factor of the nuclear receptor family, and has two isoforms, 
ERα and ERβ. Estradiol (E2) binding to ER induces a change in conformation which 
releases it from an inhibitory complex and induces dimerization.1 Regulatory proteins 
may act as either coactivators or corepressors to modulate the action of ER. Coacti-
vator proteins increase transcriptional activity of DNA elements known as estrogen 
response elements, and result in cell survival and proliferation.2 ER may also interact 
with transcription factors including Fos/Jun and modulate the activity of cyclin D1, 
and thus impact transcription of genes that do not have estrogen response elements. 
These “genomic” mechanisms are referred to as nuclear-initiated steroid signaling.
About 5%–10% of endogenous cellular ERα is located near the cytoplasmic 
  membrane.3 Membrane ERs can activate surface receptors (eg, EGFR, HER2, IGF-1R) 
or G protein-coupled receptors which then signal via classic transduction pathways 
including PI3K/Akt/mTOR and Ras/Raf/MEK/ERK.4 This results in activation of 
several kinases and phosphatases, generation of second messengers, and calcium flux. OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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This distinct “nongenomic” signaling action occurs within 
seconds to minutes, and is known as membrane-initiated 
steroid signaling.
Endocrine therapies that either interrupt the synthesis 
of estrogens or interfere with estrogen-mediated signaling 
pathways have become an integral part of the management of 
hormone-dependent breast cancer. The most commonly used 
agent of this class is tamoxifen, a selective ER   modulator. 
This review will focus on the current evidence, particularly 
for the use of tamoxifen, but also other hormonal drugs in 
ER-positive breast cancer. It will also discuss some recent 
biologic and genomic knowledge that could provide a 
mechanistic insight and may aid clinicians better identify 
those ER-positive breast cancer patients who could do well 
with tamoxifen treatment in the near future.
Tamoxifen
Tamoxifen is the most widely used hormonal treatment 
for breast cancer in both pre- and postmenopausal women. 
Adjuvant therapy with tamoxifen for five years resulted in 
a significant reduction in the annual breast cancer death rate 
of 34%, with an absolute reduction in mortality of 9.2% at 
15 years.5
The antitumor effects of tamoxifen are thought to be 
due to its antiestrogenic activity, mediated by competitive 
inhibition of estrogen binding to ER.6 As a consequence, 
tamoxifen inhibits the expression of estrogen-regulated 
genes,   including growth factors and angiogenic factors 
secreted by the tumor that may stimulate growth by autocrine 
or paracrine mechanisms.7 The net result is a block in the G1 
phase of the cell cycle and a slowing of cell proliferation. 
Tumors may then regress because of this altered balance 
between cell   proliferation and ongoing cell loss. Tamoxifen 
may also directly induce programmed cell death.8
De novo or acquired resistance may occur after treatment, 
limiting the effectiveness of tamoxifen in many patients. In at 
least some patients, the disease progresses during treatment 
because tumor growth can be stimulated by tamoxifen itself.9 
Tamoxifen-stimulated growth explains the “withdrawal 
response” that occurs in some patients when the drug is 
stopped because of tumor progression, and it explains the 
lack of response to oophorectomy in premenopausal women 
if tamoxifen is not discontinued at the time tumor progression 
is observed.10 Possible mechanisms of tamoxifen resistance 
include the presence of variant ER, the absence or loss of 
ER, altered expression of receptor-interacting proteins, and 
“cross-talk” amongst ER and other growth-factor signalling 
pathways.6,9,10
Some tumors spontaneously become hormone-independent 
despite the presence of ER; in others, tumors that are initially 
ER-positive become ER-negative over time.11,12 At least 
two-thirds of the tumors that become resistant to tamoxifen 
continue to express ER, and many of these tumors regress 
when second-line hormonal therapy is initiated.
Aromatase inhibitors
The long-term success of tamoxifen therapy has led 
to the development of other endocrine approaches. 
Because the major source of estrogen in postmenopausal 
women is   aromatase-mediated conversion of circulating 
androstenedione to estrone in peripheral tissues, an alternate 
approach to the management of postmenopausal breast cancer 
has been through the use of aromatase inhibitors.
There are two distinct mechanisms by which aromatase 
inhibitors block the action of aromatase and reduce local and 
peripheral estrogen production in postmenopausal women.13 
Type 1 inhibitors (exemestane) have androgen-like structures 
that bind irreversibly to the substrate complex, permanently 
inactivating aromatase and leading to prolonged estrogen 
deprivation. Type 2 inhibitors (letrozole and anastrozole) 
are nonsteroidal compounds that reversibly bind to the 
heme component of the aromatase enzyme. The clinical 
  significance of these differences, if any, remains to be 
  determined.14 They almost completely suppress aromatase 
activity (by 97%–99%) in postmenopausal women.
Hormone-sensitive breast cancer treated with aromatase 
inhibitors can also acquire endocrine resistance. In theory, 
an inefficient inhibition of the aromatase, either due to 
reduced drug levels or mutations/overexpression of the 
enzyme, may be implicated. Site-directed mutation can 
indeed produce aromatase that is resistant to inhibition by 
some, but not all, aromatase inhibitors.15,16 Nonetheless, 
clinical data show that changing the aromatase inhibitor 
class at disease progression (ie, from Type I to Type II, and 
vice versa) yields some clinical benefits, thus   suggesting that 
  inefficient inhibition of aromatase may drive some cases 
of disease progression. Exposure to long-term   estrogen 
deprivation and subsequent development of acquired 
resistance may be accompanied by adaptive increases in 
ER gene expression and intercellular   signalling, resulting 
in hypersensitivity to low estradiol levels.17,18   Furthermore, 
there is evidence of increased   cross-talk between the various 
growth factor-receptor signalling pathways and ER at the 
time of relapse, with ER becoming activated and supersen-
sitized by several different intracellular kinases.16 It would 
seem that, following failure of aromatase inhibitors, the ER OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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remains an integral part of the pathway sustaining tumor 
proliferation.
Further treatment with antiestrogen agents after develop-
ment of acquired resistance to aromatase inhibitors is gener-
ally accepted. Because mechanisms of acquired resistance 
to tamoxifen are thought to be similar to those developing 
after exposure to aromatase inhibitors, tamoxifen does not 
appear to be an ideal candidate to treat tumors regrowing 
after   aromatase inhibitor exposure. In such an environment 
tamoxifen may mainly act as an agonist.16 However, 
recent results of the BIG 1-98 trial do not support a   significant 
detrimental clinical effect of prescribing tamoxifen after 
letrozole, as previously hypothesized.19
Fulvestrant
The search for an antiestrogen devoid of the agonist activity 
of tamoxifen and which can effectively block ER activ-
ity resulted in the discovery and clinical development of 
fulvestrant.20,21
Fulvestrant is a pure ER antagonist, without known ago-
nistic properties, that downregulates cellular levels of the ER 
in a dose-dependent manner.22–24 It binds to the ER but, due to 
its steroidal structure and long side chain, induces a different 
conformational shape with the receptor to that achieved by the 
nonsteroidal antiestrogen, tamoxifen. As a result, fulvestrant 
prevents ER dimerization and leads to the rapid degradation 
of the fulvestrant-ER complex, producing the loss (down-
regulation) of cellular ER.25 Fulvestrant, unlike tamoxifen, 
inhibits ER-DNA binding and produces abrogation of 
estrogen-sensitive gene transcription.26 In vitro, fulvestrant 
significantly inhibits the expression of genes such as c-myb 
and c-myc in cells resistant to long-term estrogen deprivation, 
and may therefore be an appropriate therapeutic option after 
progression on aromatase inhibitors.17 Unfortunately clinical 
development of fulvestrant has been hampered by poor oral 
bioavailability, with the intramuscular route of administration 
plagued by solubility and dosage problems, and confusing 
clinical results. Despite the encouraging preclinical data, 
clinical data showed only equivalence to aromatase inhibitors 
and tamoxifen.27 It currently seems that the true potential of 
this hormonal agent may never be fully realized.
Adjuvant hormonal trials
In general, the studies that have included aromatase inhibitors 
in the treatment of postmenopausal women with early breast 
cancer have evaluated their use in three distinct ways, ie, as 
front-line adjuvant therapy for five years in substitution of 
tamoxifen (up-fronting approach), as sequential adjuvant 
therapy following 2–3 years of tamoxifen for 3–2 years 
up to a total duration of five years (switching approach), 
or as additional five years after completion of five years of 
  tamoxifen (extending approach).28,29
The ATAC trial compared five years of upfront anas-
trozole with five years of tamoxifen, or the combination of 
both.29,30 The combination arm showed no added benefit over 
the tamoxifen arm, and it was closed. A peak in recurrence at 
two years was observed in patients receiving tamoxifen, but 
not in those receiving anastrozole. At a median 100-month 
follow-up, disease-free survival was significantly improved 
in patients treated with anastrozole. No significant difference 
in overall survival was observed (see Table 1).
The BIG 1–98 trial randomized patients to either five years 
of tamoxifen, five years of letrozole, two years of tamoxifen 
followed by three years of letrozole, or two years of letrozole 
followed by three years of tamoxifen. An initial analysis, 
at a median follow-up of 25.8 months, demonstrated a 
significantly improved disease-free survival in the frontline 
letrozole arm.31 These results have also been confirmed 
at a more recent analysis (76-month median follow-up). 
However, this study did not show that either tamoxifen or 
Table 1 Summary of currently reported adjuvant hormonal therapy trials. Overall, compared with five years of tamoxifen alone, the 
incorporation of an aromatase inhibitor significantly improves disease-free survival
Study Patients (N) Last follow-up  
(months)
AI Comparator DFS HR P value OS HR P value REF
Up-front adjuvant  
ATAC 5216 100 ANA TAM 0.85 0.003 0.97 0.7 29
BiG 1-98 (MA) 4922 76 LeT TAM 0.88 0.03 0.81 0.08 31
TeAM 9766 33 eXe TAM 0.83 0.02 NR NR 33
Switch adjuvant  
ieS 4724 56 eXe TAM 0.76 0.001 0.85 0.08 34
ABCSG 8/iTA/ARNO 95 2577 84 ANA TAM 0.59 0.0001 0.71 0.04 35
Extended adjuvant  
MA.17 5187 30 LeT Placebo 0.58 0.001 0.98 0.853 36
Abbreviation: MA, monotherapy arm.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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letrozole initial therapy had a significant effect on overall 
survival. An analysis of the two sequential treatment arms 
(with a median follow-up of 71 months) reported19 that none 
of the study outcomes was significantly improved using either 
sequential therapy compared with letrozole monotherapy. 
Trends support initial use of letrozole in patients at higher risk 
of relapse. Patients commenced on letrozole can be switched 
to tamoxifen if required. Updated results of the monotherapy 
comparison suggest a trend towards superior overall survival 
with letrozole compared with tamoxifen (see Table).
The TEAM (Tamoxifen Exemestane Adjuvant Multina-
tional) trial compared upfront tamoxifen with upfront exemes-
tane. An initial analysis at 2.75 years showed a nonsignificant 
trend in disease-free survival benefit, indicating an improved 
outcome with exemestane versus tamoxifen in the intent to 
treat population.32 Excluding patients who have never received 
a study drug, disease-free survival significantly improved with 
exemestane. At a median follow-up of 5.1 years, exemestane 
monotherapy and sequential therapy achieved similar disease-
free survival and overall survival (see Table).33
The IES study compared a switch to exemestane or 
continued tamoxifen after an initial 2–3 years of tamoxifen 
therapy, for a total of five years. An eight-year follow-up 
showed the switch significantly improved both disease-free 
survival and overall survival (see Table).34
A meta-analysis of three trials (ABCGS-8, ITA, ARNO) 
comparing five years of tamoxifen with tamoxifen followed 
by anastrozole showed a significantly improved disease-free 
survival and overall survival in patients in the switching 
arms.35
The MA.17 study randomized patients who had com-
pleted 4.5–6.0 years of tamoxifen to either five years of 
subsequent letrozole therapy or placebo.36,37 At a median 
follow-up of 2.5 years, patients who continued adjuvant 
treatment with letrozole experienced significantly improved 
disease-free survival, but no change in overall survival 
(see Table). However, a retrospective subgroup analysis 
revealed a significant benefit in overall survival among 
patients with node-positive disease.
Genomic contribution to definition 
of tamoxifen-sensitive breast cancer
Current guidelines recommend the inclusion of adjuvant 
endocrine therapy in almost all patients whose tumors show 
evidence of endocrine responsiveness.38 However, the het-
erogeneity of breast cancer, clinical behavior, and response 
to endocrine treatment has long been apparent to clinicians, 
despite positive expression of ER and its related genes, and 
in the adjuvant setting up to 30% of patients with ER-positive 
breast cancer relapse despite the treatment due to either 
intrinsic or acquired resistance.5
Given the heterogeneity and complexity of breast cancer 
disease, it is probably unlikely that one predictive biomarker 
can capture and explain the differences in clinical outcome for 
all ER-positive tumors. For this reason, in recent years, whole 
genome microarray and other high-throughput technologies 
able to provide simultaneous characterization of thousands of 
genes have been extensively used in an attempt to define more 
accurate prognostic and predictive markers for breast cancer, 
and to obtain a mechanistic insight into the reasons underly-
ing sensitivity and resistance to tamoxifen treatment.
Molecular classification of breast 
cancer and prognostic implications
Unsupervised hierarchic clustering analysis has identified 
multiple molecular subgroups within breast cancer. The 
most commonly cited microarray classification divides breast 
  cancers into four main groups: the “basal-like” subtype, which 
is predominantly ER-negative, PR-negative, and HER2-
negative; the HER2-like subtype, characterized by increased 
expression of genes located in the HER2 amplicon; and at 
least two “luminal-like” subtypes, predominately ER-positive, 
named luminal A and B.39–42 Interestingly, these molecular 
phenotypes were associated with distinct clinical outcomes. 
When originally described, the luminal A subgroup had the 
highest expression of ER and ER-regulated genes and a   better 
clinical outcome compared with the luminal B subgroup, 
  suggesting an underlying molecular basis of the   heterogeneity 
of clinical outcome in breast   cancer. Relevant to this review 
article, a group of ER-positive cancers that had an   unfavorable 
outcome even when treated with adjuvant endocrine   treatment 
could be observed.40 These data heralded much early excite-
ment and reinforced to clinicians and scientists alike that 
breast cancer subtypes were likely to need different thera-
peutics and that the biology of disease progression was prob-
ably unique for each subgroup. Unfortunately, despite these 
seminal publications, clinically implemented   stratification of 
luminal A and B subtypes is currently rare.
Several predictive gene sets and assays have been 
developed over recent times to aid clinicians identify those 
ER-positive breast cancers that have a poor clinical outcome 
despite tamoxifen treatment in the hope of determining 
which patients may be suitable for tamoxifen, either alone 
or sequentially, and those with a poor prognosis who may OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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require chemotherapy, aromatase inhibitors, or other tar-
geted strategies.43–47 One of the most successful assays was 
developed by Genomic Health using quantitative real-time 
polymerase chain reaction and was derived by analyzing the 
results from three preliminary studies involving 447 samples 
from a heterogeneously treated population (chemotherapy 
and tamoxifen) and 250 candidate genes selected after a 
literature search of the most important microarray experi-
ments relating to breast cancer prognosis.43 Of these, 21 genes 
were chosen, five of which were control genes; the derived 
multigene predictor assigned a “recurrence score” to   predict 
low-, intermediate-, and high-risk of distant recurrence 
for women receiving five years of adjuvant tamoxifen 
(± chemotherapy).
The predictor was subsequently validated prospectively 
in archival patients who had received tamoxifen only in 
the NSABP B-14 trial. The recurrence score accurately 
predicted patients at high-risk versus low-risk of recur-
rence on tamoxifen, identifying those who do poorly with 
tamoxifen treatment. The recurrence score is currently the 
subject of a global Phase III randomized trial evaluating 
its ability to select ER-positive breast cancer patients for 
either adjuvant hormonal treatment alone or with standard 
chemotherapy.
The gene expression grade index (GGI) score is based 
on 97 genes found to be consistently differentially expressed 
between low (Grade 1) and high (Grade 3) histologic grade 
breast cancer.49 Not surprisingly, these genes are mainly 
involved in cell cycle regulation, proliferation, apoptosis 
evasion, and differentiation. Of note, the GGI was shown to 
be able to define two distinct molecular subgroups within ER-
positive breast cancer that were highly comparable with the 
previously defined luminal A and B classification. The sam-
ples previously classified as luminal A or B were associated 
with significantly different GGI values, with luminal A sub-
types being associated with low GGI values and the luminal B 
tumors having significantly higher GGI values. Of note, these 
two subtypes were associated with   statistically distinct out-
comes in both systematically untreated and   tamoxifen-treated 
populations.47,49 These studies were important because they 
reinforced the hypothesis that the proliferative phenotype 
is associated with a poor prognosis in   ER-positive breast 
cancer, thus highlighting a group not suitable for tamoxifen 
monotherapy and a group with a   critical need for further 
research. The molecular “drivers” of the   luminal B or highly 
proliferative ER-positive phenotype, and what may be its best 
therapeutic strategy remain to be   determined. It is probable 
that a few molecular targets will emerge, such as PIK3CA 
and FGFR1 amplification. As such, it is   currently far from 
clear if aromatase inhibitors, fulvestrant, or   chemotherapy 
can change the natural disease history of this subgroup. 
Future integrative genomic and deep sequencing studies may 
shed further biologic light for these breast cancer patients 
in the future. However, it is imperative that clinical trials 
prospectively stratify for luminal prognostic subtypes using 
some measure of tumor proliferation activity. Markers such 
as Ki67 immunohistochemistry, histologic grade, GGI, or 
recurrence score may be useful in this regard.
Gene expression predictors  
of response to endocrine treatment
While molecular profiling of breast cancer has shown the 
existence of different prognostic tumor phenotypes within 
the ER-positive population, determining if any of these gene 
signatures could act as a predictive biomarker of benefit from 
endocrine agents rather that just prognosis (ie, independent 
of treatment) has been more difficult. Many of the aforemen-
tioned studies involved tumors that had been treated with 
tamoxifen, but a poor prognosis may be related to inherent 
tumor aggressiveness as well as tamoxifen resistance.
The recurrence score has been reported to be predictive 
of tamoxifen response. In particular, a low recurrence score 
is considered predictive of tamoxifen benefit in ER-positive, 
node-negative cases, while a high recurrence score is predic-
tive of chemotherapy benefit over hormonal therapy in ER-
positive patients, regardless of lymph node status.48,50,51
In the recent past, several other gene expression signa-
tures have been developed in an attempt to predict sensitivity 
or resistance to both tamoxifen and aromatase inhibitors.52–55 
In a recent study, Symmans et al52 hypothesizing that mea-
surement of gene expression related to ER within a breast 
cancer sample represents intrinsic tumor sensitivity to 
adjuvant endocrine therapy, were able to define a genomic 
index for sensitivity to endocrine therapy (SET index) from 
genes coexpressed with the ESR1 gene in 437 microarray 
profiles from newly diagnosed breast cancer, unrelated to 
treatment or outcome. The association of the SET index and 
ESR1 levels with distant relapse risk was evaluated from 
microarrays of ER-positive breast cancer in two cohorts who 
received five years of tamoxifen alone as adjuvant endocrine 
therapy, a cohort who received neoadjuvant chemotherapy 
followed by tamoxifen and/or aromatase inhibitor, and two 
cohorts who received no adjuvant systemic therapy. The SET 
index (165 genes) was significantly associated with distant OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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relapse or death risk in both tamoxifen-treated cohorts and 
in the chemoendocrine-treated cohort independent of the 
pathologic response to chemotherapy, but was not prognostic 
in two untreated cohorts. No distant relapse or death was 
observed after tamoxifen alone if node-negative and high 
SET, or after chemoendocrine therapy if intermediate or high 
SET. The SET index was found to be useful in   estimating 
distant relapse-free survival if patients were to receive 
adjuvant endocrine therapy alone and in conjunction with 
other clinicopathologic information to determine whether 
or not additional treatment might be indicated to improve 
the likelihood of cure further.52
Kok et al45,56 evaluated if their 78-gene signature that 
was developed from a dataset of metastatic breast cancer 
patients who did and did not respond to tamoxifen treatment 
was truly predictive of tamoxifen response. They found that 
their signature seemed to be more predictive than prognostic 
compared with the recurrence score in an independent set 
of tamoxifen-treated ER-positive metastatic breast cancer 
patients. Whilst the metastatic setting may be the most logical 
way to investigate the true predictive ability of a biomarker, 
it remains plausible that metastatic breast cancer patients 
have different disease biology compared with those having 
early-stage disease.
Miller et al54 used the neoadjuvant or preoperative setting 
to uncover gene profiles for which baseline expression and 
relative change with 14 days of treatment differed between 
breast cancers that were clinically responsive or resistant to 
letrozole therapy. The advantage of the neoadjuvant setting 
is that it allows multiple ways of assessment of response 
to therapy, eg, monitoring of changes in tumor size during 
the first months of treatment and sequential tumor biopsies 
before and after neoadjuvant treatment with letrozole. Gene 
expression profiles were then related to clinical responses 
as assessed from tumor volume measurements after three 
months of   treatment. Bioinformatic analysis identified 
205 probe sets (69 baseline expression, 45 day 14 expression, 
and 91 changes in expression with treatment) which dif-
ferentiated between clinical responders and nonresponders. 
Of note, the high proportion of change and day 14 variables 
among the total emphasizes the need to monitor the effects 
of therapy on gene expression as well as baseline param-
eters when identifying predictive markers of response to 
treatment.54 This study underscores the potential of the 
neoadjuvant setting for high-level correlative science, but 
also supports the need for biologically driven hypotheses 
and stratification of luminal subtypes, and also highlights the 
difficulties of serial analyses using high-dimensional data.
Important genetic aberrations  
in ER-positive patients
Some key genetic aberrations have been identified in recent 
years that can impact ER signaling and response to   endocrine 
therapy. These aberrations may occur at the ER and other 
related surface receptor level (HER1, HER2, IGFR-1, 
FGFR-1), signaling pathway (PI3K, MAPK) level, and tran-
scription factor level (myc, cyclin D1). It is important to note, 
that luminal A and B remains terminology for a phenotype, 
and that understanding the molecular aberration/s that drive the 
phenotype is likely to be critical for better outcomes. Following 
are some recent findings on the molecular alterations of key 
genes related to the ER pathway, their luminal phenotype and 
their potential clinical implications.
HeR2
When ER binds to tamoxifen, it undergoes a conformational 
change that favors the recruitment of corepressors that inhibit 
transcriptional activity.57 The subset of ER-positive patients 
who are also HER2-positive are known to have a relatively 
poor response to tamoxifen. Patients whose tumors express 
high levels of both HER2 and the ER coactivator AIB1 
(amplified in breast cancer 1) often develop tamoxifen resis-
tance.58 Shou et al showed that addition of tamoxifen to the 
MCF-7/HER2-18 cell lines which overexpress both AIB1 
and HER2 in fact resulted in growth stimulation.57
Ellis et al have reported that when neoadjuvant tamoxifen 
was administered, there was a significantly lower clinical 
response rate among patients with HER2 amplified tumors 
(33%) as compared with the HER2 negative ones (49%).59 
They also reported that HER2 positivity was associated 
with a lower suppression of Ki67, a marker of cell prolif-
eration, in response to tamoxifen. Hence, HER2+ is one 
driver of the luminal-B phenotype. Given its clinical and 
therapeutic implications, it should always be distinguished 
from other ER-positive cancers, including other luminal-B 
type cancers.
PiK3CA
PIK3CA mutations are seen in about 26% of breast cancers, 
especially in ER-positive and HER2-overexpressing subtypes 
(www.sanger.ac.uk/perl/genetics/CGP/cosmic). These muta-
tions are frequently located in hotspots on exons 9 (helical 
domain) and 20 (kinase domain).60 The prognostic implica-
tions of this aberration are unclear, but recent data suggest it 
is likely that this mutation is associated with a relatively good 
prognosis for ER-positive, HER2-negative breast cancer.60–63 
Although the exact mechanism for this is unclear, using gene OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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expression and protein data from around 1800 breast tumor 
samples, we have reported that in ER-positive and HER2-
negative tumors, PIK3CA mutations were associated with 
relatively low mTORC1 signaling despite the presence of 
constitutive pathway activation, and with a good clinical 
outcome from single-agent tamoxifen. Increased sensitivity 
to tamoxifen has been also observed in PI3K mutant cell 
lines compared with wild-type, so this aberration may have 
important clinical implications.
PIK3CA and PIK3CB amplifications have been found 
in a minority of breast cancers.64 Amplification of this gene 
may have different functional effects compared with muta-
tion for breast cancer. A more aggressive phenotype was 
reported with PIK3CA amplification compared with mutation 
in endometrial cancer.65
AKT1
AKT1 mutations have been found in around 4% of breast 
cancers and have also been shown to be tumorigenic through 
activation of PI3K signaling.66 Whilst the association with 
tamoxifen and outcome is not known, AKT1 mutations were 
reported to have a gene expression profiles similar to those 
of PIK3CA mutants, suggesting that AKT1 mutations may 
also be associated with a relatively good clinical outcome 
from tamoxifen therapy.61 These hypotheses remain to be 
validated further in the clinical setting, and are highly relevant 
given the current intense interest in the development of PI3K 
pathway inhibitors.
FGFR1
Amplification of FGFR1 occurs in around 10% of breast 
cancers,67,68 and amplification of FGFR1 has been associated 
with a poor prognosis in ER-positive breast cancer.69 Of note, 
HER2 and FGFR1 amplification rarely coexist, suggesting 
overlapping areas of pathway activation. FGFR1 amplifica-
tion has been shown to be associated with the luminal B, 
ER-positive phenotype with high levels of proliferation, and 
hence may be a realistic potential therapeutic target for this 
poor prognostic group given that a number of drugs exist 
that inhibit this molecule.70 Additionally, FGFR1-amplified 
cell lines were shown to be resistant to tamoxifen, and this 
resistance was reversed by siRNA silencing of FGFR1. 
FGFR1-amplified tumors are frequently PR-negative.
Myc and cyclin D1
Musgrove et al have suggested that estrogen regulates cell 
growth principally via c-Myc.71 Overexpression of c-Myc 
and cyclin D1 occurs in 38% (range 11%–70%) and 45% 
(range 28%–81%) of breast cancer patients and has been 
associated with tamoxifen resistance.72 Because these genes 
are involved with cell cycle regulation and proliferation activ-
ity, it is plausible that these aberrations also may be drivers 
of the luminal B phenotype.
Limitations of current genomic 
predictors
Despite their promise, none of aforementioned molecular 
aberrations, except for HER2, or gene signatures identified 
thus far has been approved for routine use in the clinical 
setting. There are a multitude of different reasons for this, 
from lack of appropriate clinical validation, unclear clinical 
implications, technical reasons involving standardization of 
the assay, tissue requirement (snap-frozen), and cost.
Although gene expression profiling has given us new 
insights into the biology of ER-positive breast cancer, a 
consistent definition of clinically relevant ER-positive sub-
groups is lacking. A widely accepted and standard definition 
could significantly help research in the field. Clinical trials 
could then be conducted in stratified populations because 
important therapy effects may be diluted or missed by ana-
lyzing an unselected ER-positive population. Whilst mea-
surement of proliferation gene expression may provide a 
good starting point, the cutoff between luminal A and B 
groups is somewhat arbitrary due to the fact there is no clear 
biologic bimodality and that proliferation   activity is a con-
tinuum. It will also be necessary in the future to include 
genetic aberrations as upfront stratification due to their dif-
fering influences on clinical outcome and response to 
therapy. Figure 1 demonstrates how our knowledge of the 
key genetic aberrations involved in the pathogenesis of the 
luminal subtypes has become a little clearer even in the last 
few years.
Whilst prognostic gene signatures have been consistently 
shown to be helpful in ER-positive breast cancers, they seem 
only to identify early relapses (within five years) and hence 
much of the biology underlying late relapse which is com-
mon in ER-positive breast cancer, and therefore prediction 
of it is unknown. We are also not sure to what extent gene 
predictors provide better prognostication than currently 
widely available clinicopathologic factors. A recent study 
reported that a four-marker surrogate immunohistochemi-
cal panel (ER, PR, HER2, and Ki67) was able to define a 
luminal B phenotype. This group, together with luminal/
HER2-positive tumors, was found to have worse relapse-
free and breast cancer-specific survival compared with 
luminal A tumors, both in the presence and in the absence OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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of adjuvant systemic treatment with either tamoxifen alone 
or combination chemotherapy and tamoxifen.73 Notably for 
this study, all of these “standard” markers were performed 
in one central laboratory, emphasizing the poor reproduc-
ibility and quantification of local immunohistochemistry. 
The future may become clearer with the development of 
truly “predictive” biomarkers for tamoxifen response and 
resistance, and it is expected that a better understanding of 
the molecular drivers of ER-positive breast cancer using 
new deep and integrative genomic techniques will probably 
emerge. Furthermore, it has become apparent that it will be 
important to perform these correlative studies in the context 
of clinical trials to understand their clinical implications 
more accurately.
Can we identify patients who will  
do well with tamoxifen alone?
In general, the aforementioned studies that have evaluated the 
use of aromatase inhibitors versus tamoxifen have consistently 
shown that adding an aromatase inhibitor during adjuvant 
therapy improves disease-free survival and reduces the risk of 
breast cancer events compared with five years of tamoxifen 
monotherapy (see Table 1). However, if we look at absolute 
percentages, the reduction in risk of recurrence associated with 
aromatase inhibitors compared with tamoxifen could be con-
sidered disappointing. Upfront comparisons of tamoxifen and 
aromatase inhibitors are the same in terms of overall survival, 
supporting a main reduction from local and contralateral events 
(ie, not life-threatening) and even provocatively implying a 
worse outcome for aromatase inhibitor-treated patients after 
relapse and increased deaths from other causes (see Table 1). 
Two of the six trials of sequential treatment strategies yielded 
statistically significant improvements in overall survival com-
pared with tamoxifen alone, although again the absolute dif-
ference in overall   survival was small. Furthermore, aromatase 
  inhibitors are not always well tolerated and are considerably 
more expensive than tamoxifen.
However, breast cancer events and early recurrence are 
important, and given that metastatic disease is incurable, 
the current standard is to include an aromatase inhibitor in 
the adjuvant treatment of postmenopausal women.74 Only a 
minority of postmenopausal women who decline or have a 
contraindication to an aromatase inhibitor currently receive 
tamoxifen alone. Because aromatase inhibitors do not sup-
press ovarian estrogen synthesis fully, they cannot be used 
for the treatment of premenopausal women.75
Recently, Viale et al developed a risk nomogram includ-
ing tumor size, tumor grade, hormone receptor status, and 
HER2 status, to generate a risk model that could allow cat-
egorization of breast cancer patients into three groups, with 
low-, intermediate-, or high-risk outcomes.76 Low-risk patients 
achieved excellent outcomes regardless of the treatment type. 
However, as the risk of relapse increased, differences between 
the aromatase inhibitor-based treatments began to emerge. 
Therefore, there may still be a role for using five years of 
tamoxifen therapy for these lower-risk women.
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in reference 47. Previously the gene expression grade index (GGi) was used as a measure of proliferation activity to divide eR-positive breast cancer into luminal A and B 
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Research in the genomic field continues to advance our 
understanding of the biologic basis of relapse for ER-positive 
breast cancer, but clinical implementation of such findings 
remains slow. Currently it seems that the luminal A phenotype 
could do quite well with tamoxifen alone for five years. This 
subgroup could be identified in multiple ways, using either 
an immunohistochemical or gene expression assay that can 
quantify the expression of proliferation genes in a given 
breast cancer. Genetic aberrations, such as HER2 and FGFR1 
amplification, could also define clearly for clinicians, without 
relying on arbitrary, nonbiologic cutoff for the luminal B 
phenotype, those ER-positive patients who will do poorly 
with tamoxifen treatment alone.
Conclusion
Tamoxifen treatment remains highly relevant for women 
diagnosed with ER-positive breast cancer. It is also clear that 
distinct luminal phenotypes exist and should be character-
ized by some proliferation marker in clinical trials, given 
that the treatment in the future is likely to be different for 
each. We feel that the most significant advances in the field 
of predictive biomarkers and biologic understanding will 
only occur in the context of innovative trials that incorporate 
prospectively planned translational research in their design. 
Hence, strong and respectful collaboration between basic 
researchers, clinicians, and pharmaceutical companies will 
be required in order to accomplish the challenging objec-
tive of a “personalized” treatment for ER-positive breast 
cancer patients.
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